TY - JOUR
T1 - PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer
AU - Burgio, Salvatore L.
AU - Conteduca, Vincenza
AU - Rudnas, Britt
AU - Carrozza, Francesco
AU - Campadelli, Enrico
AU - Bianchi, Emanuela
AU - Fabbri, Paolo
AU - Montanari, Marco
AU - Carretta, Elisa
AU - Menna, Cecilia
AU - De Giorgi, Ugo
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background The aim of this study was to assess early serum prostate-specific antigen (PSA) changes in patients treated with abiraterone and to correlate those changes with clinical outcome. Patients and Methods We retrospectively evaluated 103 patients with castrate-resistant prostate cancer (CRPC) treated with compassionate use of abiraterone in Romagna, Italy. In these patients, serum PSA levels were monitored every 4 weeks, and a time course of serum PSA levels was obtained. The PSA flare phenomenon was evaluated. The log-rank test was applied to compare survival between groups of patients according to early PSA level changes. Results Of 103 patients, 43 (41.7%) had an immediate PSA response, whereas 9 (8.7%) had an initial PSA flare. Of the 9 patients with PSA flare, 5 attained a subsequent PSA response. The temporary PSA flare exceeded baseline values by a median of 19.7% (range, 5%-62.9%). The median PFS of the 9 patients in the PSA-flare group was higher compared with patients without the PSA flare (10.5 vs. 6.4 months; P =.0999) but was similar to the subgroup of patients with immediate PSA response (10.5 vs. 10.7 months; P =.7019). In the multivariate analysis, only the PSA response remained as a predictor of progression-free survival (PFS) (P
AB - Background The aim of this study was to assess early serum prostate-specific antigen (PSA) changes in patients treated with abiraterone and to correlate those changes with clinical outcome. Patients and Methods We retrospectively evaluated 103 patients with castrate-resistant prostate cancer (CRPC) treated with compassionate use of abiraterone in Romagna, Italy. In these patients, serum PSA levels were monitored every 4 weeks, and a time course of serum PSA levels was obtained. The PSA flare phenomenon was evaluated. The log-rank test was applied to compare survival between groups of patients according to early PSA level changes. Results Of 103 patients, 43 (41.7%) had an immediate PSA response, whereas 9 (8.7%) had an initial PSA flare. Of the 9 patients with PSA flare, 5 attained a subsequent PSA response. The temporary PSA flare exceeded baseline values by a median of 19.7% (range, 5%-62.9%). The median PFS of the 9 patients in the PSA-flare group was higher compared with patients without the PSA flare (10.5 vs. 6.4 months; P =.0999) but was similar to the subgroup of patients with immediate PSA response (10.5 vs. 10.7 months; P =.7019). In the multivariate analysis, only the PSA response remained as a predictor of progression-free survival (PFS) (P
KW - Abiraterone
KW - Castration-resistant prostate cancer
KW - Outcome
KW - Progression
KW - PSA flare
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84920583134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920583134&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2014.06.010
DO - 10.1016/j.clgc.2014.06.010
M3 - Article
C2 - 24999168
AN - SCOPUS:84920583134
SN - 1558-7673
VL - 13
SP - 39
EP - 43
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 1
ER -